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The following changes were made to the article by Wright RS, Anderson JL, Adams CD, et al., “2011 ACCF/AHA
Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial
Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines” as it appeared in the May 10, 2011, issue of the Journal (J Am Coll Cardiol
2011;57:1920–59) after it published ahead of print on March 28, 2011:
• On the first page (p. 1920), the American Academy of Family Physicians was deleted from the line beginning “Developed
in Collaboration With . . .” because they had been incorrectly included while endorsement of the document was pending.
• The title of Table 2 has been changed to “Recommendations for Early Hospital Care Antiplatelet Therapy.”
• The titles of Section 5.2.1 and Table 5 have been changed to “Recommendations for Convalescent and Long-Term
Antiplatelet Therapy.” The text of the document and the Table of Contents have been changed accordingly.
• In Table 5, in the second and third rows, the 2007 recommendations previously indicated “Deleted recommendation (see
Table 2, Class I, #1 and #7)” in the third column. For the purpose of clarity, those recommendations are now included as
#2 and #3 in the table. Hence, in the fourth row, 2011 Class I Recommendation #2 is now #4 and the second and third rows
of Table 5 are now presented as follows:
• In the Appendix 6 flowchart, the third bullet of the step “Initiate anticoagulant therapy (Class I, LOE: A); Acceptable
options include” contained an error. It was corrected to read “Enoxaparin or fondaparinux preferred over UFH (Class
IIa, LOE: B).”
hese changes have all been made to the article as published in the May 10, 2011, issue. doi:10.1016/j.jacc.2011.04.002
Redwine LS, Wirtz PH, Hong S, et al. Depression as a Potential Modulator of Beta-Adrenergic–Associated
Leukocyte Mobilization in Heart Failure Patients. J Am Coll Cardiol 2010;56:1720–7.
On the first page, author Jos Bosch should have been listed as Jos A. Bosch.
Recommendations for Convalescent and Long-Term Antiplatelet TherapyTable 5 Recommendations for Convalescent and Long-Term Antiplatelet Therapy
2007 Recommendations 2011 Focused Update Recommendations Comments
For UA/NSTEMI patients treated with a
BMS, ASA* 162 to 325 mg per day
should be prescribed for at least 1 month
(Level of Evidence: B), then continued
indefinitely at a dose of 75 to 162 mg
per day (Level of Evidence: A); clopidogrel
should be prescribed at a dose of 75 mg
per day for a minimum of 1 month and
ideally for up to 1 year (unless the
patient is at increased risk of bleeding;
then it should be given for a minimum of
2 weeks). (Level of Evidence: B)
2. For UA/NSTEMI patients treated with a BMS, ASA*
162 to 325 mg per day should be prescribed for at
least 1 month (Level of Evidence: B), then
continued indefinitely at a dose of 75 to 162 mg
per day. (Level of Evidence: A) The duration and
maintenance dose of thienopyridine therapy should
be as follows:
a. Clopidogrel 75 mg daily (17) or prasugrel†
10 mg daily (22) should be given for at least 12
months (13,17). (Level of Evidence: B)
b. If the risk of morbidity because of bleeding
outweighs the anticipated benefits afforded by
thienopyridine therapy, earlier discontinuation
should be considered. (Level of Evidence: C)
Modified recommendation (to be concordant with
2009 STEMI and PCI Focused Update [32]).
For UA/NSTEMI patients treated with a DES,
ASA* 162 to 325 mg per day should be
prescribed for at least 3 months after
sirolimus-eluting stent implantation and
6 months after paclitaxel-eluting stent
implantation, then continued indefinitely
at a dose of 75 to 162 mg per day.
(Level of Evidence: B) Clopidogrel 75 mg
daily should be given for at least 12
months to all post-PCI patients receiving
DES. (Level of Evidence: B)
3. For UA/NSTEMI patients treated with a DES, ASA*
162 to 325 mg per day should be prescribed for at
least 3 months after sirolimus-eluting stent
implantation and 6 months after paclitaxel-eluting
stent implantation (Level of Evidence: B), then
continued indefinitely at a dose of 75 to 162 mg
per day. (Level of Evidence: A). The duration and
maintenance dose of thienopyridine therapy should
be as follows:
a. Clopidogrel 75 mg daily (17) or prasugrel†
10 mg daily (22) should be given for at least 12
months (13,17). (Level of Evidence: B)
b. If the risk of morbidity because of bleeding
outweighs the anticipated benefits afforded by
thienopyridine therapy, earlier discontinuation
should be considered. (Level of Evidence: C)
Modified recommendation (to be concordant with
2009 STEMI and PCI Focused Update [32]).The authors apologize for this error. doi:10.1016/j.jacc.2010.11.009
